NeuraMetrix

NeuraMetrix’ Mission is to support Neurologists and Psychiatrists with an accurate and passive digital biomarker to detect, monitor, and assess the efficacy of a particular treatment for various Neurological diseases and Psychiatric disorders
Business Description

NeuraMetrix develops a passive digital brain health monitoring platform that detects and monitors neurological diseases and psychiatric disorders by measuring typing inconsistency, a strong indicator of cognitive and motor performance. The company's platform uses proprietary algorithms to analyze sub-second keystroke timing during normal computer use, enabling researchers and healthcare providers to track disease progression and treatment efficacy for conditions such as Alzheimer's, Parkinson's, Huntington's, and Depression.

The Story Behind NeuraMetrix

NeuraMetrix, Inc. set out to eliminate the need for passwords. The team searched for strong behavioral biometrics, i.e., strong habits. Habits must be mimicked, which is much harder for hackers to replicate. The company studied various habits and found Typing Cadence (the rhythm with which we type on a keyboard) to be an extremely strong habit. The company then pursued developing a product for continuous authentication of enterprise employees.

In a meeting, someone suggested that NeuraMetrix technology could detect Alzheimer’s Disease (AD). This intrigued our co-founder, Jan Samzelius, to seek advice from an AD expert. After a search, Jan was introduced to Dr. Robert W. Mahley, M.D. Ph.D., President Emeritus and Founder, Gladstone Institutes, Senior Investigator, Gladstone Institute of Neurological Disease, Professor of Pathology and Medicine, University of California, San Francisco, and mentor to the 2012 Nobel Prize winner in the medicine category. Twenty minutes into the conversation, Dr. Mahley exclaimed, “This is what we have been looking to find for 30 years!” That afternoon, we pivoted the company into neurotech.
​​​​​​​
As a result, we developed the NeuraMetrix passive digital brain health biomarker, which detects neurological diseases and psychiatric disorders at much earlier stages, providing significantly improved patient care.

NeuraMetrix Timeline

Q1 2027

CRO's Alzheimer's study to start

Summer 2025

End of 4-year American Heart Association & Boston University heart problems and dementia study

December 2023

Winner of Hitlab Fall 2023 Breakthrough Alliance Challenge

HitLab, a significant digital health accelerator, received 485 applications and first narrowed it down to 5 finalists. We were one of the five. Then, live, they selected three winners. We were one of the three.

September 2023

Awarded grant from the NIH

NeuraMetrix, together with Rutgers University, awarded a grant from the National Institutes of Health (NIH) for a 5-year clinical study.

Spring 2023

Patent approved in the European Union

Patent is now being issued

Fall 2022

First contract with Harvard University

November 2021

Awarded a Japanese patent

NeuraMetrix awarded Japanese patent 6959911

August 2021

Awarded two additional U.S. patents

NeuraMetrix awarded two additional U.S. patents US 11,079,856 and US 11,100,201

Summer 2021

Major pharma running pilot test with NeuraMetrix

Signed an agreement for a pilot study to assess the usability and reliability of the NeuraMetrix TC digital biomarker platform

April 2021

Boston University have selected NeuraMetrix for a major brain health study

NeuraMetrix' Digital Brain Health Biomarker is selected for participation in Boston University's Precision Brain Health Initiative

March 2021

Published Research Paper on using NeuraMetrix TC to measure Huntington's Disease

Our paper 'Monitoring the Motor Phenotype in Huntington's Disease by Analysis of Keyboard Typing During Real Life Computer Use' was published in the Journal of Huntington's Disease

January 2021

Signed Distributor for the Latin America markets

NeuraMetrix and bioaccess™ Sign Agreement to Commercialize NeuraMetrix' Breakthrough Mental and Brain Health Technology in Latin America

November 2020

Awarded one Australian Patent

NeuraMetrix awarded Australian Patent 2016268858

April 2020

Awarded Two U.S. Patents

NeuraMetrix awarded U.S. Patents 10,694,947 and 10,694,987

February 2020

First to detect if Huntington's is active without visible symptoms

Research determined that NeuraMetrix TC can detect if Huntington's is active without visible symptoms allowing earlier treatment resulting in better care

September 2019

First Paying Customers

A leading academic neurology institution signed up to use NeuraMetrix in their practice

August 2019

First to establish Digital 'Fingerprints' for Parkinson's, Huntington's, and Depression

NeuraMetrix first to establish digital 'fingerprints' of the disease/disorder for Parkinson's, Huntington's, and Depression

July 2019

Signs agreement for business development in Asia and the Pacific

NeuraMetrix signs an agreement with N-Strategy Consulting Services (NSCS) to accelerate NeuraMetrix's market entry into Asia and the Pacific

May 2019

CE Mark

Registered CE Mark for the European market

January 2019

Granted 'Breakthrough Device' Designation

FDA granted Breakthrough Device designation to NeuraMetrix for a device "that provides more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions"

Fall 2014

Demonstrated statistical quality far beyond any existing measures

Research demonstrated that the NeuraMetrix digital biomarker has a statistical quality far beyond any existing measures.

NeuraMetrix today consists of six experienced team members spread across the United States, Europe, and Asia. The company has raised funding through equity investments.